{"id":"W4391609515","doi":"10.1093/bjd/ljad498.028","title":"523 - Efficacy and safety of amlitelimab (an anti-OX40 ligand antibody) in patients with moderate-to-severe atopic dermatitis: 24-week results from a phase 2b trial (STREAM-AD)","year":2024,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"","keywords":"Atopic dermatitis; Medicine; Dermatology; Internal medicine; Antibody; Gastroenterology; Pediatrics; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001700697,0.0008722047,0.00151954,0.0002577517,0.000295172,0.0007411569,0.0004715102,0.0009609286,0.005122893],"category_scores_gemma":[0.00100689,0.0002919167,0.001175631,0.000182323,0.000551865,0.0006046454,0.0002438268,0.00170893,0.001031972],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006131802,"about_ca_system_score_gemma":0.0007309351,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004454489,"about_ca_topic_score_gemma":0.001241188,"domain_scores_codex":[0.9995216,0.0002502162,0.00003374628,0.00007461195,0.00004591635,0.00007399863],"domain_scores_gemma":[0.9994295,0.000110453,0.0001335716,0.00004443188,0.00006248033,0.0002195259],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8769125,0.02618304,0.005964437,0.0007427308,0.000878579,0.000118353,0.0001186246,0.0004902697,0.02032776,0.0001309891,0.004128292,0.06400434],"study_design_scores_gemma":[0.7561589,0.2223026,0.01520994,0.00004737352,0.00049136,0.0001665696,0.0000278045,0.000662877,0.002329201,0.0001278172,0.002455323,0.00002034428],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9914944,0.002968815,0.0002752016,0.0003665174,0.0001227457,0.001904548,0.001025911,0.00007147569,0.001770484],"genre_scores_gemma":[0.990202,0.001186004,0.001160981,0.0006997827,0.0002711698,0.001917859,0.001599516,0.00001644754,0.002946339],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005122893,"threshold_uncertainty_score":0.01713783,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01112127489176316,"score_gpt":0.2772268404591704,"score_spread":0.2661055655674072,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}